FN Media Group Presents USA News Group News Commentary
Vancouver, BC –October 6, 2021 – USA News Group – As vaccine passport programs continue to roll out in new markets across the globe, especially in Europe and North America, it appears that the argument remains unsettled, as vaccine in many parts of the world vaccine hesitancy and refusal persists. So while multiple injections have been authorized for emergency use in the leadup to where we are now, there are still others that are working through different phases of trials with alternative forms of delivery and technology, including from BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF), Novavax, Inc. (NASDAQ:NVAX), Sanofi (NASDAQ:SNY), GlaxoSmithKline plc (NASDAQ:GSK) and Inovio Pharmaceuticals, Inc. (NASDAQ:INO).
By partnering with $63-billion Chinese bio manufacturer WuXi Biologics, BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF) announced it’s moved one step closer with its COVID-19 vaccine candidate BVX-0320, which utilizes haptenized protein technology based on the work of the immunologist and Nobel laureate Dr. Karl Landsteiner.
BVX-0320 works by initiating a T cell-mediated immune response to SARS-CoV-2. T-cells (or T-lymphocytes, which are white blood cells that are crucial in tumor rejection) react against the haptenized material and that the T-cells also then react against the unmodified target protein.
In vivo studies have demonstrated that BVX-0320, BioVaxys’ monovalent haptenized s-spike protein vaccine, stimulated a 96.4% antibody response, activation of CD4+ helper T cells and CD8+ killer T cells, and stimulation of T cells that produce the cytokine, gamma interferon.
The deal with WuXi involves the biologic manufacturing of synthesized high yields of fully characterized, SARS-CoV-2 s-protein for BioVaxys‘ Good Laboratory Practice (GLP) safety studies.
BioVaxys President & Chief Operating Officer Kenneth Kovan said, “The production of the recombinant s-protein using WuXi Biologics‘ proprietary cell expression system is a significant milestone for Biovaxys, as we not only have a high production yield of protein, but also now have the ability and know-how to produce protein in large scale with the level of purity, consistency and protein characterization required by the FDA for our clinical studies and commercial-scale yields.”
The company is currently in research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320.
BioVaxys continues to assess steps to develop a multivalent version of BVX-0320 to address newly emerging SARS-CoV-2 variants such as the highly transmissible United Kingdom (B.1.1.7 lineage), South Africa (B.1.351 lineage), and Brazil (P.1 lineage) that are of high concern to worldwide governments, healthcare practitioners, and infectious disease researchers.
Not too late to the party, Novavax, Inc. (NASDAQ:NVAX) is set to test its Covid-19 vaccine candidate in another UK trial. The study is designed to explore heterologous regimen of Covid-19 vaccines from different manufacturers in adolescents 12-16 years of age.
Expanding our understanding of how different COVID-19 vaccines can be used to implement flexible vaccine programs across all age groups will be vital to ultimately controlling the pandemic,” said Gregory M. Glenn, M.D., President of Research and Development, Novavax. “A mixed vaccination series could offer the potential to maximize the use of existing vaccine supply, increase the total number of individuals who can ultimately be vaccinated and accelerate rapid and equitable access across the globe.”
Also catching up is the joint work of French pharma giant Sanofi (NASDAQ:SNY) and partners GlaxoSmithKline plc (NASDAQ:GSK), which is now in its Phase 3 trial.
Already, Spain has committed to buying 500,000 doses of the new Sanofi-GSK Covid-19 vaccine, which the makers hope to get approval for by the end of 2021. The total order of all the EU Member States is estimated to be 72 million doses. The Sanofi-GSK offering is also an mRNA delivery, much like those of Pfizer and Moderna.
Down in South America, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is heading into Brazil for its phase 3 Covid-19 vaccine trial, for its DNA vaccine candidate INO-4800.
So far, INO-4800 has a strong safety profile and, unlike other COVID-19 vaccine candidates, INO-4800 is administered intradermally and has caused only very limited side effects (mostly mild injection site reactions).
“With many countries in the world experiencing low vaccination rates and seeing an increase in infections, we feel the urgency to advance INO-4800 globally,” said Dr. J. Joseph Kim, President and CEO of INOVIO. “I am incredibly proud of the INOVIO team and grateful to the health authorities in Brazil for their commitment to advancing the fight against COVID-19. INOVIO’s focus on supporting the global response to the pandemic is unwavering – and will bring forward the potential advantages of INO-4800, which in addition to being well-tolerated with balanced neutralizing antibodies and T cell responses (CD8 and CD4), has a strong thermostability profile, and potentially offers the ability to serve as both a primary as well as a booster vaccine.”
For more information, please visit: https://biotech-today.com/heres-why-you-want-biotech-stocks-in-your-portfolio/
USA News Group
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for BioVaxys Technology Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares of BioVaxys Technology Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of BioVaxys Technology Corp. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of BioVaxys Technology Corp. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
U.S. Phone: +1(954)345-0611
SOURCE USA News Group